

**Corporate Profile**

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were \$21.9 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com).

**Recent Headlines**

November 02, 2017

Teva Announces Completion of Plan B One-Step® Divestiture to Foundation  
Consumer Healthcare

---

November 02, 2017

Teva Reports Third Quarter 2017 Financial Results

---

November 01, 2017

Teva Announces Completion of PARAGARD® Divestiture to CooperSurgical

---

**Primary IR Contact**


Investor Relations

**Phone:** (215) 591-3034**E-mail:**[TevaIRus@tevapharm.com](mailto:TevaIRus@tevapharm.com)**Upcoming Events**

There are currently no events scheduled.

## Analyst Estimates / Ratings

Mean Recommendation: **3.0**



## EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Dec 17	0.75	1.11	1.18
QTR	Mar 18	0.68	0.97	1.07
QTR	Jun 18	0.69	0.98	1.07
QTR	Sep 18	0.66	0.97	1.08
FY	Dec 17	3.82	4.23	4.31
FY	Dec 18	2.95	3.79	4.02

## SEC Filings

Filing Date	Form
11/13/17	SC 13D/A
11/02/17	6-K
11/02/17	6-K
11/02/17	6-K

## Financial Reports

Date	
05/11/17	First Quarter 2017 Earnings Press Release

## Presentations

Date	
11/02/17	Teva Third Quarter Results 2017 Presentation

### Corporate Officers

**Dr. Yitzhak Peterburg**  
Interim President and CEO

**Iris Beck-Codner**  
Group EVP, Corporate Marketing & Communications

**Dipankar Bhattacharjee**  
President and Chief Executive Officer, Global Generic Medicines Group Group Executive Vice President, Human Resources

**Dr. Hafrun Fridriksdottir**  
Executive Vice President, President of Global Generics R&D

**Dr. Michael Hayden**  
President of Global R&D and Chief Scientific Officer

**Dr. Rob Koremans**  
President and CEO, Global Specialty Medicines

**Michael McClellan**  
Senior Vice President, Interim Chief Financial Officer

**Dr. Carlo de Notaristefani**  
President and Chief Executive Officer, Global Operations

**Mark Sabag**  
Group Executive Vice President, Human Resources

**David M. Stark**  
Group Executive Vice President, Chief Legal Officer

**Nir Baron**  
Executive Vice President, Chief Internal Auditor